Abstract
Refractory ventricular fibrillation (RVF) represents a critical medical emergency, with high mortality and limited response to advanced resuscitation protocols. This review aims to identify the current causes, electrocardiographic features, pathophysiology, and emerging evidence-based treatments through 2025.
References
- Bartnik M., et al. “Extracorporeal Cardiopulmonary Resuscitation in Refractory Ventricular Fibrillation”. Journal of the American College of Cardiology 81.7 (2023): 712-723.
- Callaway CW., et al. “Part 8: Advanced Cardiovascular Life Support: 2020 American Heart Association Guidelines”. Circulation 142.16_suppl_2 (2020): S366-S468.
- Cheskes S., et al. “Early Versus Delayed Double Sequential External Defibrillation for Refractory Ventricular Fibrillation: A Randomized Trial”. Circulation 145.1 (2022): 9-18.
- Kern KB., et al. “Advanced Cardiovascular Life Support: Beyond the Basics”. Resuscitation 152 (2020): 236-245.
- Moe GW., et al. “Sudden Cardiac Death: Global Epidemiology and Therapeutic Challenges”. Lancet Cardiology 8.3 (2023): 210-223.
- Panchal AR., et al. “2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care”. Circulation 138.23 (2018): e740-e749.